Kosaka Y, Tameda Y, Okita K, Takemoto T, Sato S, Okuda K, Kameda H, Yamamoto S, Kamada T, Muto Y
First Department of Internal Medicine, School of Medicine, Mie University, Tsu, Japan.
Gastroenterol Jpn. 1987 Dec;22(6):737-42. doi: 10.1007/BF02776747.
The effects of ranitidine on plasma clearance of ICG were investigated in 68 cirrhotic patients (9 were positive for HBsAg, 33 were alcoholics and 26 had cryptogenic cirrhosis). The ICG clearance test was performed before and after ranitidine administration. In 31 patients treated with ranitidine (150 mg perorally), the plasma ICG clearance were 233.6 +/- 20.4 ml/min (mean +/- S.E.) and 239.2 +/- 20.5 ml/min before and after ranitidine, respectively. In the 37 treated with intravenous ranitidine 50 mg, the corresponding values were 205.4 +/- 17.7 ml/min and 206.4 +/- 17.9 ml/min. There was no significant change in the plasma clearance of ICG or the elimination rate constant after ranitidine administration. Even in patients with decompensated liver cirrhosis, no significant change was demonstrated in the plasma ICG clearance after ranitidine. These results led to the conclusions that ranitidine does not reduce the hepatic blood flow and that it is a safe and useful drug for the treatment of gastrointestinal tract bleeding in patients with liver cirrhosis.
在68例肝硬化患者（9例乙肝表面抗原阳性，33例为酗酒者，26例为隐源性肝硬化）中研究了雷尼替丁对吲哚氰绿（ICG）血浆清除率的影响。在给予雷尼替丁之前和之后进行ICG清除试验。在31例接受雷尼替丁治疗（口服150毫克）的患者中，雷尼替丁给药前后血浆ICG清除率分别为233.6±20.4毫升/分钟（平均值±标准误）和239.2±20.5毫升/分钟。在37例接受静脉注射50毫克雷尼替丁治疗的患者中，相应的值分别为205.4±17.7毫升/分钟和206.4±17.9毫升/分钟。给予雷尼替丁后，ICG的血浆清除率或消除速率常数没有显著变化。即使在失代偿期肝硬化患者中，雷尼替丁给药后血浆ICG清除率也没有显著变化。这些结果得出的结论是，雷尼替丁不会降低肝血流量，并且它是治疗肝硬化患者胃肠道出血的一种安全有效的药物。
